In last trading session, AIM ImmunoTech Inc (AMEX:AIM) saw 0.37 million shares changing hands with its beta currently measuring -0.30. Company’s recent per share price level of $0.20 trading at $0.0 or 0.45% at ring of the bell on the day assigns it a market valuation of $13.66M. That closing price of AIM’s stock is at a discount of -210.0% from its 52-week high price of $0.62 and is indicating a premium of 20.0% from its 52-week low price of $0.16. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.84 million shares which gives us an average trading volume of 640.06K if we extend that period to 3-months.
For AIM ImmunoTech Inc (AIM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.09 in the current quarter.
AIM ImmunoTech Inc (AMEX:AIM) trade information
Upright in the green during last session for gaining 0.45%, in the last five days AIM remained trading in the red while hitting it’s week-highest on Monday, 01/27/25 when the stock touched $0.20 price level, adding 11.11% to its value on the day. AIM ImmunoTech Inc’s shares saw a change of 1.97% in year-to-date performance and have moved -5.70% in past 5-day. AIM ImmunoTech Inc (AMEX:AIM) showed a performance of -3.86% in past 30-days. Number of shares sold short was 0.49 million shares which calculate 1.63 days to cover the short interests.
AIM ImmunoTech Inc (AIM) estimates and forecasts
Statistics highlight that AIM ImmunoTech Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -43.90% of value to its shares in past 6 months, showing an annual growth rate of 50.00% while that of industry is 17.20. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to fall -0.99% from the last financial year’s standing.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 100k for the same. Company posted 65k and 40k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 42.86% during past 5 years.
AIM ImmunoTech Inc (AMEX:AIM)’s Major holders
Insiders are in possession of 8.57% of company’s total shares while institution are holding 14.07 percent of that, with stock having share float percentage of 15.39%. Investors also watch the number of corporate investors in a company very closely, which is 14.07% institutions for AIM ImmunoTech Inc that are currently holding shares of the company. ARMISTICE CAPITAL, LLC is the top institutional holder at AIM for having 4.08 million shares of worth $1.52 million. And as of 2024-06-30, it was holding 8.2454 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 1.99 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.021 of outstanding shares, having a total worth of $0.74 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.31 shares of worth $0.26 million or 2.06% of the total outstanding shares. The later fund manager was in possession of 620.23 shares on Sep 30, 2024 , making its stake of worth around $0.13 million in the company or a holder of 0.97% of company’s stock.
